Synektik

Synektik S.A. Secures Major Contract for da Vinci Surgical System Delivery

On October 27, 2025, Synektik S.A., a leading Polish medical technology company, announced the signing of a significant contract with the Provincial Hospital in Bielsko-Biała. The agreement, valued at PLN 12,320,891.91 net, involves the delivery, installation, and commissioning of the da Vinci robotic surgical system, along with necessary equipment, personnel training, and warranty-period servicing. The contract was awarded through an open public tender, and the delivery is expected to be completed within 90 days of signing.

This development underscores Synektik S.A.'s position as the exclusive distributor of the da Vinci robotic surgical systems in Poland and highlights its commitment to advancing minimally invasive surgical technologies in the healthcare sector.

Synektik S.A. Secures Major Contract for Robotic Surgery System Delivery to Bielsko-Biała Hospital

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Provincial Hospital in Bielsko-Biała for the delivery, installation, and commissioning of the da Vinci robotic surgery system. The contract, valued at PLN 12,320,891.91 net, also includes staff training and comprehensive service support during the 60-month warranty period. The project will be financed through the National Recovery and Resilience Plan, with the system set to be delivered within 90 days of the agreement's signing.

The deal was finalized following a public procurement process and is considered a key milestone for Synektik S.A., as its value exceeds 5% of the company’s equity, as reported in its latest financial statement. The revenue from this project will contribute to the company’s financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This agreement underscores Synektik S.A.'s leadership in the distribution of advanced medical technologies, particularly the da Vinci robotic surgery system, aligning with its core business focus on innovative healthcare solutions and strengthening its market position in Poland.

Synektik S.A. Secures Major Contracts for Robotic Surgery Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of several significant contracts between October 20 and October 23, 2025, for the delivery and installation of advanced robotic surgery systems. These agreements highlight the company's growing presence in the healthcare sector and its commitment to providing cutting-edge medical solutions.

• October 20, 2025: Synektik signed a contract with the Provincial Hospital Complex in Elbląg for the supply, installation, and training related to the da Vinci robotic surgery system and the APOTECAchemo system for cytostatic drug preparation. The contract is valued at PLN 15,492,111.11 net.
• October 21, 2025: The company finalized an agreement with Szpitale Pomorskie Sp. z o.o. in Gdynia for the delivery and installation of the da Vinci robotic surgery system at the Specialist Hospital in Wejherowo. The contract is worth PLN 9,251,585.51 net.
• October 23, 2025: Synektik secured a deal with the Oncology Center in Poznań for the installation of the fifth-generation da Vinci robotic surgery system. The contract value is PLN 16,180,000.00 net.

Each contract includes comprehensive services such as equipment installation, personnel training, and warranty-period maintenance, ensuring seamless integration into the respective healthcare facilities.

Relevance to Synektik S.A. Profile: These contracts reinforce Synektik's position as a leader in robotic surgery systems and advanced medical technologies, aligning with its core business model of delivering innovative healthcare solutions.

Synektik S.A. Secures Major Contract for da Vinci 5 Surgical System with Wielkopolskie Centrum Onkologii

Synektik S.A., a leading Polish medical technology company, has announced the signing of a significant agreement with Wielkopolskie Centrum Onkologii in Poznań. The contract, valued at PLN 16,180,000.00 net, involves the delivery, installation, and commissioning of the fifth-generation da Vinci 5 robotic surgical system, along with necessary equipment, staff training, and warranty-period service support.

The agreement was finalized following a public procurement process and stipulates that the system will be delivered within 10 weeks of signing. The warranty period for the system extends to 36 months from the final acceptance protocol. The deal is considered a key milestone for Synektik S.A., as its value exceeds 5% of the company’s equity, as reported in its latest financial statement. Revenue from this project will contribute to the company’s financial results for FY2025, spanning October 2025 to September 2026.

This development underscores Synektik S.A.'s position as a leader in advanced medical technologies, particularly in robotic surgery, aligning with its business focus on distributing cutting-edge systems like the da Vinci platform and providing comprehensive service solutions.

Synektik S.A. Secures Contract for da Vinci Surgical System with Szpitale Pomorskie

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with Szpitale Pomorskie Sp. z o.o. for the sale, delivery, installation, and commissioning of the da Vinci robotic surgical system. The system, designed for minimally invasive surgeries, will be installed at the Specialist Hospital F. Ceynowy in Wejherowo. The contract also includes additional equipment, staff training, and a 36-month warranty with service support. The deal, valued at PLN 9,251,585.51 net, was awarded through a public procurement process and is expected to be fulfilled within 60 days of signing.

The agreement is considered a key milestone for Synektik S.A., as its value represents 5% of the company’s equity, as reported in its latest financial statement. Revenue from this contract will contribute to the company’s financial results for FY2025, spanning from October 1, 2025, to September 30, 2026.

Relevance: This contract aligns with Synektik S.A.'s core business focus on distributing advanced medical technologies, including the da Vinci surgical system, and reinforces its position as a leader in robotic surgery solutions in Poland.

Synektik S.A. Secures Major Contracts for Robotic Surgery and Cytostatic Drug Preparation Systems

Synektik S.A., a leading Polish medical technology company, has announced the signing of significant contracts with the Provincial Integrated Hospital in Elbląg. The agreements, valued at a net total of PLN 15,492,111.11, involve the delivery, installation, and commissioning of the da Vinci robotic surgery system and the APOTECAchemo robotic system for cytostatic drug preparation. The contracts also include staff training and comprehensive service support during the warranty period.

The procurement was conducted through an open tender process and will be financed by the National Recovery and Resilience Plan. The da Vinci system is expected to be delivered within 12 weeks, while the APOTECA system will be delivered within 20 weeks. The warranty periods are set at 84 months for the da Vinci system and 60 months for the APOTECA system, starting from the signing of final acceptance protocols. The revenue from these contracts will contribute to Synektik's financial results for FY2025, spanning October 2025 to September 2026.

The contracts are deemed significant as their combined value exceeds 5% of Synektik Group's equity, as reported in the latest financial statement, meeting the company's internal reporting standards.

Relevance: This development aligns with Synektik S.A.'s core business focus on providing advanced medical technologies, including robotic surgery systems, and reinforces its position as a key player in the Polish healthcare technology market.

Da Vinci 5: Revolutionizing Robotic Surgery with Advanced Innovations

The fifth-generation da Vinci surgical robot introduces 150 groundbreaking innovations, significantly enhancing precision, ergonomics, and operator control. Key advancements include a more powerful computational system, smoother arm movements, and a redesigned console offering high-resolution 3D imaging and personalized settings. A major breakthrough is the integration of Force Feedback technology, enabling surgeons to "feel" tissue resistance, improving safety and precision during procedures. These enhancements reduce surgery times by 15-20%, minimize complications, and lower healthcare costs by shortening patient recovery periods and hospital stays.

Da Vinci 5 is also future-ready, designed for integration with artificial intelligence, real-time data analysis, and augmented reality, paving the way for decision-support systems and remote surgical education. Despite increasing competition from Chinese robotic systems, the da Vinci platform maintains its edge with a robust clinical base, extensive training networks, and proven reliability, ensuring its continued leadership in robotic surgery.

This article is relevant to Synektik S.A. as the company is the exclusive distributor of da Vinci systems in Poland, aligning with its focus on delivering cutting-edge medical technologies and solutions to healthcare providers.

Polish Medical Supply System Shows Strengths but Requires Updates and Better Coordination

The Polish medical supply system for individually prescribed medical devices has been recognized as efficient, stable, and patient-friendly, but experts highlight the need for regular updates and improved coordination among public institutions. A report by POLMED and INNOWO titled “Medical Devices Issued on Prescription – The Polish System Compared to Neighboring Countries in the Context of Socio-Health Challenges” provides a comprehensive analysis of the system's financing and functionality.

In 2023, Poland issued nearly 413 million medical devices on prescription, ranging from incontinence pads and ostomy bags to wheelchairs, hearing aids, orthoses, and prosthetics. Public funding for these devices amounted to PLN 2.67 billion, averaging PLN 70.9 per capita—the lowest in Central Europe. Despite lower spending, Poland’s flexible financing model ensures strong health outcomes and faster access to innovative technologies compared to neighboring countries. This model allows patients to co-decide on product selection and adapt to market changes, making it resilient to economic shocks such as rising costs of raw materials and transportation.

However, challenges remain, including the aging population, outdated product lists, and fragmented funding sources (NFZ and PFRON). The report recommends regular updates to the product list, indexed funding limits, and streamlined coordination of funding sources. It also suggests involving national consultants, clinicians, patient groups, and industry representatives in the review process, with updates occurring at least every two years. Additionally, transparent procedures for introducing new product categories and adequate vacatio legis periods for regulatory changes are proposed.

Experts emphasize the importance of adapting the system to demographic shifts, technological advancements, and economic realities to ensure better access to modern medical devices and improved patient care.

Relevance to Synektik S.A.: The article highlights the importance of innovation and efficient distribution systems in the medical device sector, aligning with Synektik S.A.'s role as a leading distributor of advanced medical technologies and solutions in Poland.

Synektik S.A. Secures Major Contract for da Vinci Surgical System Supplies

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the State Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw. The contract, valued at a maximum net amount of PLN 9,851,541.97, involves the supply of consumables for the da Vinci robotic surgical system used in minimally invasive procedures. The agreement, awarded through an open tender process, will span 12 months and adheres to standard contractual practices for such arrangements.

The deal is considered crucial by Synektik's management as its value exceeds 5% of the Group's equity reported in the latest financial statement, marking it as a material transaction under the company's internal reporting standards. Revenue from this contract is expected to positively impact Synektik's financial results for fiscal years 2025 and 2026.

Relevance: This agreement underscores Synektik's leadership in distributing advanced medical technologies, including the da Vinci surgical system, aligning with its core business model and strengthening its market position in Poland.

Synektik Introduces Revolutionary da Vinci 5 Surgical System to Poland

Synektik S.A., the exclusive distributor of Intuitive Surgical's da Vinci systems in Poland, has unveiled the fifth-generation da Vinci 5 surgical robot, marking a significant milestone in robotic-assisted surgery. This cutting-edge platform, equipped with over 150 technical innovations and enhanced computational power, enables surgeons to perform minimally invasive procedures with unprecedented precision, real-time data analysis, and seamless collaboration. The system integrates advanced features such as Force Feedback technology, immersive 3D visualization, and automated functionalities, ensuring greater autonomy and efficiency for surgeons.

Since 2018, over 33,000 procedures have been performed in Poland using da Vinci systems, with 73 robots currently operational across the country. Synektik has trained more than 300 operators and numerous surgical teams, solidifying Poland's position as a regional leader in robotic surgery. The da Vinci 5 system further enhances surgical workflows by integrating multiple technologies into a single platform, reducing the need for additional personnel and simplifying operations. Its applications span various specialties, including urology, gynecology, general surgery, and thoracic surgery, supporting over 200 types of procedures.

Synektik's comprehensive approach to implementing robotic surgery includes international certification training, technical support, and ongoing expertise, ensuring the successful adoption of this transformative technology. The introduction of da Vinci 5 underscores the company's commitment to advancing healthcare innovation and improving patient outcomes.

Relevance to Synektik S.A.: This article highlights Synektik's pivotal role in bringing advanced robotic surgical systems to Poland, aligning with its business model of distributing cutting-edge medical technologies and supporting healthcare innovation.

Shurui: A Revolutionary Surgical Robot Challenging Market Leaders

Beijing Surgerii Robotics Company Limited has unveiled Shurui, a groundbreaking surgical robot featuring a dual-continuum mechanism made of flexible nitinol rods, enabling multi-directional bending of instruments. The system supports multi-port, single-port, and hybrid procedures, making it the first of its kind to offer such versatility. Shurui has received CE certification for adult and pediatric procedures in urology, gynecology, general surgery, and thoracic surgery, positioning it as a competitive alternative to Intuitive Surgical's da Vinci systems.

Priced at approximately €2.28 million, Shurui is slightly cheaper than the da Vinci SinglePort (€2.77 million) but more expensive than other Chinese multi-port systems. The robot has already performed over 2,000 surgeries across 70 hospitals in China and 10 European centers, with plans for further expansion in Europe and potential approval in the U.S. Its inclusion in IRCAD's training program in Strasbourg highlights its growing prominence in the global surgical robotics market.

Shurui's innovative design includes manipulators inspired by snake anatomy, offering unmatched dexterity in confined spaces. The system's smaller port diameter (25–26 mm) addresses limitations of da Vinci SP in thoracic surgery, while its pediatric certification provides a competitive edge. Additionally, Shurui has demonstrated capabilities in remote surgeries, showcasing its reliability and precision in telemedicine applications.

Comparative studies have shown Shurui's performance to be on par with da Vinci SP in prostatectomy outcomes, while its advanced features, such as reduced port size and hybrid procedure support, make it a strong contender in the surgical robotics market.

Relevance to Synektik S.A.: The emergence of Shurui highlights increasing competition in the surgical robotics market, directly impacting Synektik S.A., the exclusive distributor of da Vinci systems in Poland. Understanding advancements like Shurui is crucial for Synektik to maintain its market position and adapt to evolving technologies.

Polish Parliament Approves Centralized Hospital Resource Monitoring System

The Polish Parliament has passed a law to establish the Central System for Monitoring Hospital Resources, known as the Provider Potential Registry (EPS). The system, developed by the Ministry of Health, will enable real-time tracking of hospital resources, including beds, medical staff, essential medical supplies, protective equipment, medical gases, and blood. The initiative aims to enhance pre-hospital care by reducing patient rejections at emergency departments and minimizing unnecessary patient transfers between hospitals. Additionally, the system will improve resource management during crises such as pandemics, natural disasters, or military conflicts. EPS will automate data collection directly from hospital IT systems, ensuring efficient reporting and enabling better decision-making in critical situations. The law also phases out COVID-19-specific data reporting requirements, which were introduced during the pandemic but never fully implemented.

Relevance to Synektik S.A.: The implementation of EPS aligns with Synektik S.A.'s focus on advanced IT solutions for healthcare, such as its PACS imaging systems and Zbadani.pl platform, highlighting potential opportunities for the company to contribute to the system's technological infrastructure.

Synektik Secures Medical Equipment Orders Worth 145 Million PLN in Q4 FY 2024

Synektik S.A., a leading Polish medical technology company, has announced a significant increase in orders for medical equipment in the fourth quarter of the fiscal year 2024. The company secured contracts worth approximately 145 million PLN, marking a substantial growth compared to the 82.7 million PLN in orders obtained during the same period last year. This achievement underscores Synektik's expanding presence in the medical equipment market and its ability to meet growing demand for advanced healthcare solutions.

The relevance of this development lies in Synektik's core business model, which focuses on the distribution of cutting-edge medical equipment and IT solutions for healthcare, aligning with its strategic goals and market leadership in Poland.

Healthcare Spending in Poland Reaches 243.8 Billion PLN in 2023

According to data released by the Central Statistical Office (GUS) in the Monitor Polski, Poland's total healthcare spending in 2023 amounted to 243.8 billion PLN, marking a 24% increase compared to 2022's expenditure of 196.2 billion PLN. Public spending accounted for 189.1 billion PLN, with 162.4 billion PLN derived from mandatory health insurance systems and 26.8 billion PLN from government and local administration budgets. Private spending reached 54.7 billion PLN, including 38.6 billion PLN in direct household expenses and 16 billion PLN in other private expenditures.

This significant rise in healthcare investment highlights the growing demand for advanced medical technologies and services, aligning with Synektik S.A.'s focus on providing cutting-edge medical equipment, IT solutions, and radioisotopes for diagnostic imaging.

Synektik S.A. Reports Significant Growth in Medical Equipment Orders for FY 2024

Synektik S.A., a leading Polish medical technology company, has announced a substantial increase in orders within its medical equipment, IT solutions, and services segment. The company secured approximately 391 million PLN in orders for the 2024 financial year, compared to 360 million PLN in 2023. Notably, orders in Q4 2024 reached 145 million PLN, nearly doubling the 82.7 million PLN recorded in Q4 2023.

As of September 30, 2025, the backlog of orders awaiting fulfillment stood at 75.9 million PLN, a significant rise from 36.1 million PLN a year earlier. Additionally, the value of active offers at the end of the period increased to 198.7 million PLN, up from 141.5 million PLN in 2024. These figures are preliminary estimates and will be confirmed in the company’s interim financial report for the period ending September 30, 2025.

The growth in orders highlights Synektik’s strong market position and its ability to meet increasing demand for advanced medical technologies, including robotic surgical systems and diagnostic imaging solutions.

Relevance: This development underscores Synektik S.A.'s leadership in the medical technology sector, aligning with its business model of providing cutting-edge medical equipment and IT solutions to healthcare institutions.

Milickie Centrum Medyczne Advances Orthopedic Surgery with Robotic System Velys

Milickie Centrum Medyczne Advances Orthopedic Surgery with Robotic System Velys

Izabela Laber-Napora, Head of the Rehabilitation Department, emphasized the importance of integrated care, noting that patients are transferred directly to rehabilitation within the same facility, ensuring faster recovery. Dr. Zbigniew J. Król, CEO of the hospital, described the investment in Velys as part of a broader strategy to position the hospital as a modern and patient-friendly healthcare center in the Dolina Baryczy region.

Milickie Centrum Medyczne is the third hospital in Poland to adopt the Velys system, following the Clinical Hospital of the Medical University of Łódź. The robotic system, developed by Johnson & Johnson, assists surgeons by analyzing patient anatomy in real-time and optimizing implant placement. Across Poland, over 20 hospitals utilize robotic systems for joint replacement surgeries, including Velys, Cori (Smith & Nephew), Rosa (Zimmer Biomet), Mako (Stryker), and OmniBotics. Some facilities have also expanded robotic applications to hip replacements.

Relevance to Synektik S.A.: This article highlights the growing adoption of robotic systems in Polish healthcare, a market where Synektik S.A. plays a key role as the exclusive distributor of the da Vinci surgical robot and a leader in advanced medical technologies.

Expansion of PET/CT Indications in Poland Set for January 2026

Starting January 2026, Poland will implement expanded indications for PET/CT imaging, enabling earlier detection and more effective treatment for a broader range of patients. The updated guidelines, outlined in a draft regulation by the President of the National Health Fund, include approximately 20 clinical scenarios eligible for public funding. This marks a significant milestone for nuclear medicine, as advocated by the Polish Society of Nuclear Medicine and other medical experts.

Key advancements include the introduction of PSMA-based radiopharmaceuticals for prostate cancer diagnostics, which outperform traditional fluorocholine methods by detecting cancer at lower PSA levels. Additionally, PET/CT imaging will now be available for neuroendocrine tumors, cervical and endometrial cancers, and non-cancerous conditions like parathyroid adenomas. These updates align Poland with European standards, enhancing diagnostic precision and therapeutic outcomes.

Experts emphasize the transformative impact of these changes, including improved patient prognoses, reduced healthcare costs, and better alignment with modern oncological practices. The expanded indications will also facilitate the use of cutting-edge radiopharmaceuticals and imaging techniques, addressing longstanding gaps in Poland's diagnostic capabilities.

Relevance to Synektik S.A.: As Poland's leading producer and supplier of radiopharmaceuticals, Synektik S.A. stands to benefit significantly from the increased demand for advanced PET/CT imaging solutions, reinforcing its position in the medical technology market.

Synektik Introduces Cutting-Edge Robotic Surgery Systems to Polish Market

Synektik S.A., a leading Polish medical technology company, has expanded its portfolio with the introduction of the latest generation da Vinci 5 robotic surgery system and the single-port da Vinci SP model. The company also launched the Ion endoluminal system for advanced pulmonary bronchoscopy diagnostics. These innovations mark a significant step in enhancing precision and efficiency in minimally invasive procedures.

The da Vinci 5 system, designed with machine learning capabilities and advanced AI algorithms, offers enhanced computational power and introduces haptic feedback for improved surgical precision. Priced at approximately 13 million PLN, it is 30% more expensive than its predecessor, the da Vinci Xi. The single-port da Vinci SP, priced at 12 million PLN, enables surgeries through a single incision, making it ideal for specialized procedures such as radical prostatectomy and head-and-neck surgeries.

Synektik also unveiled the Ion system, priced at 6 million PLN, which provides unparalleled accuracy in lung biopsies. With features like 180-degree maneuverability, fiber-optic construction, and advanced path-planning capabilities, Ion significantly reduces diagnostic time for lung cancer. While no Polish hospitals currently use Ion, its adoption is growing globally, with over 900 units operational in the U.S.

Synektik now manages 77 da Vinci robots in Poland, with projections of over 20,000 robotic surgeries in 2025. The company has trained more than 300 Polish surgeons and plans to open a training center in Warsaw, complementing its existing facility in Prague. Globally, Intuitive Surgical deployed 1,790 new robots in 2024, with a growing trend toward leasing and shared-use models. In total, 2.68 million surgeries were performed using da Vinci systems last year, underscoring their transformative impact on healthcare.

“2025 marks the 30th anniversary of robotic surgery development by Intuitive Surgical, a technology aimed at improving patient outcomes and expanding access to minimally invasive treatments,” said Cezary Kozanecki, founder and CEO of Synektik.

Relevance: This article highlights Synektik's strategic role in introducing advanced robotic systems to Poland, aligning with its business model of distributing cutting-edge medical technologies and supporting healthcare innovation.

Synektik S.A. Appoints Tomasz Wróbel as New Board Member to Drive Operational Transformation

Synektik S.A., a leading Polish medical technology company, has announced the appointment of Tomasz Wróbel as a Member of the Management Board, effective October 1, 2025. The decision was made by the Supervisory Board on September 22, 2025. Wróbel will serve as Chief Operating Officer, focusing on the standardization, integration, and digital transformation of internal processes.

According to official statements, Wróbel does not engage in any competitive activities or hold positions in competing entities. Additionally, he is not listed in the National Debtors Register. His professional background and qualifications are detailed in an accompanying document.

This appointment aligns with Synektik S.A.'s strategic focus on innovation and operational excellence, supporting its leadership in medical technologies, including robotic surgery systems and radiopharmaceuticals.

Synektik S.A. Secures Major Contract for Robotic Surgery System Installation in Zamość Hospital

Synektik S.A., a leading Polish medical technology company, has signed a significant agreement with the Independent Public Provincial Hospital named after Pope John Paul II in Zamość. The contract involves the delivery, installation, and commissioning of the da Vinci robotic surgery system, alongside adaptation and modernization of the hospital's operating block. Additionally, the agreement includes personnel training and service support during the 36-month warranty period.

The project, valued at PLN 19,131,798.99 net, was awarded through a public procurement process and will be financed by the National Recovery and Resilience Plan. The robotic system is expected to be delivered within eight months of the contract signing. The revenue generated from this project will contribute to Synektik's financial results for the fiscal year 2025-2026.

This contract is deemed significant by Synektik's management as its value exceeds 5% of the company's equity, as reported in its latest financial statement. The agreement aligns with Synektik's strategic focus on providing cutting-edge medical technologies and services to healthcare institutions.

Relevance: This development underscores Synektik's leadership in distributing advanced robotic surgery systems and highlights its commitment to expanding its footprint in Poland's healthcare sector.